Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12015748 | 0.93 | ALDH1A1 (0.64) | MEN1KMT2AALDH1A1KDM4EHTT | |
| SCHEMBL18427237 | 0.90 | ALDH1A1 (0.56) | MEN1KMT2AALDH1A1KDM4EHTT | |
| SCHEMBL11977008 | 0.87 | KDM4E (0.63) | MEN1KMT2AALDH1A1KDM4EHTT | |
| SCHEMBL11977010 | 0.86 | KMT2A (0.64) | MEN1KMT2AALDH1A1KDM4EHTT | |
| SCHEMBL4547947 | 0.86 | KDM4E (0.62) | MEN1KMT2AALDH1A1KDM4EHTT | |
| SCHEMBL982378 | 0.85 | KDM4E (0.63) | MEN1KMT2AALDH1A1KDM4EHTT | |
| SCHEMBL12204148 | 0.84 | KDM4E (0.58) | MEN1KMT2AALDH1A1KDM4EHTT | |
| SCHEMBL15701621 | 0.84 | MEN1 (0.62) | MEN1KMT2AALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL14578276 | 0.84 | ALDH1A1 (0.69) | ALDH1A1KDM4EHTTTSHRSMN1; SMN2 | |
| SCHEMBL12015820 | 0.84 | KDM4E (0.57) | MEN1KMT2AALDH1A1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348456-A1 | QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-11-02 | — | — | US | disclosed |
| US-20230348456-A1 | QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | REPARE THERAPEUTICS INC. (CA) | 2023-11-02 | — | — | US | disclosed |
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230234959-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230234959-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-29 | — | — | US | disclosed |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
| US-20220133736-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-05-05 | — | — | US | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-13 | — | — | US | disclosed |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2008-03-13 | — | — | US | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | MEN1 3138/4885KMT2A 2222/4885ALDH1A1 1780/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | MEN1 3655/4885KMT2A 3391/4885ALDH1A1 1649/4885 |
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | MEN1 3174/4885KMT2A 830/4885ALDH1A1 2583/4885 |
| US-20220133736-A1 | USES OF PYRIMIDOPYRIMIDINONES AS SIK INHIBITORS | SIK2, SIK1, SIK3 | MEN1 4515/4885KMT2A 2339/4885ALDH1A1 1744/4885 |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | MEN1 1165/4885KMT2A 811/4885ALDH1A1 3553/4885 |
| US-20080064718-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | MEN1 3231/4885KMT2A 2353/4885ALDH1A1 3139/4885 |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | SOST, SIK2, SIK1 | MEN1 3184/4885KMT2A 1338/4885ALDH1A1 4790/4885 |
| US-20230348456-A1 | QUINAZOLINONES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME | CSNK1A1, CSNK1G1, CSNK1G3 | MEN1 728/4885KMT2A 837/4885ALDH1A1 3276/4885 |
| US-20230234959-A1 | BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF | SIK1, SIK2, SIK3 | MEN1 4493/4885KMT2A 2530/4885ALDH1A1 3729/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | MEN1 3231/4885KMT2A 2353/4885ALDH1A1 3139/4885 |
| US-11725011-B2 | Bicyclic urea kinase inhibitors and uses thereof | SIK1, SIK2, SIK3 | MEN1 4493/4885KMT2A 2530/4885ALDH1A1 3729/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | MEN1 2645/4885KMT2A 2804/4885ALDH1A1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.